Phase II study of gemcitabine in patients with advanced pancreatic cancer
1996

Gemcitabine for Advanced Pancreatic Cancer

Sample size: 34 publication Evidence: low

Author Information

Author(s): J Carmichael, U Fink, RCG Russell, MF Spittle, AL Harris, G Spiessi, J Blatter

Primary Institution: ICRF Clinical Oncology Unit, Churchill Hospital, Oxford, UK

Hypothesis

Does gemcitabine improve outcomes in patients with advanced pancreatic cancer?

Conclusion

Gemcitabine shows modest activity in advanced pancreatic cancer with some symptomatic benefits and a mild toxicity profile.

Supporting Evidence

  • Two patients achieved a partial response lasting 5.8 and 5.2 months.
  • Six patients had stable disease for at least 4 weeks.
  • The median duration of survival for evaluable patients was 6.3 months.
  • 74% of dose administrations were given on schedule.
  • Haematological toxicity was mild, with no grade 4 toxicities reported.

Takeaway

This study tested a medicine called gemcitabine on people with a serious type of cancer. It helped a few people feel better, but it didn't work for everyone.

Methodology

An open-label, single-arm study evaluating gemcitabine in chemonaive patients with advanced pancreatic cancer.

Limitations

The study had a small sample size and a low response rate.

Participant Demographics

34 patients, with 60.6% having metastatic disease, and a mean age of 56 years.

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication